US pharmaceutical company Xcovery Holdings Inc announced on Monday an agreement with EVERSANA, a provider of commercialisation services to the global life sciences industry, to support and expand the US commercial launch of Ensacove (ensartinib), the company's novel therapy for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Ensacove (ensartinib) is a next generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals Co Ltd. It is indicated for the treatment of adult patients with ALK-positive locally advanced or metastatic NSCLC as detected by an FDA-approved test who have not previously received an ALK inhibitor and is now available in the United States as a treatment for these patients.

Under the agreement, EVERSANA will provide comprehensive end-to-end commercialisation services for Xcovery, including agency of record, market access, commercial and medical teams to support the company's strategy to make Ensacove available to more patients across the US.